News

BioPharma Dive4d
Sanofi to acquire Blueprint for up to $9.5B
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Fierce Pharma4d
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
pharmaphorum2d
ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa
The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact
Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...
Vietnam Investment Review on MSN13h
MoH and Sanofi partner to advance lifelong vaccination nationwide
The Ministry of Health is partnering with Sanofi to boost immunisation drives and public awareness from 2025-2027.
Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...
Medical Marketing & Media1d
Rx Rundown: Merck, Sanofi, Eli Lilly and more
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...